 Blair Fennimore
Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Inflammatory Bowel Diseases | 5 | 2022 | 320 | 0.980 |
Why?
| | Colon | 3 | 2020 | 252 | 0.740 |
Why?
| | Colitis | 2 | 2020 | 241 | 0.710 |
Why?
| | Mucoproteins | 1 | 2020 | 10 | 0.700 |
Why?
| | Cholestasis | 2 | 2020 | 232 | 0.700 |
Why?
| | Cholangitis, Sclerosing | 1 | 2020 | 71 | 0.660 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 173 | 0.640 |
Why?
| | Bile Acids and Salts | 1 | 2020 | 195 | 0.620 |
Why?
| | Gastrointestinal Diseases | 2 | 2015 | 198 | 0.510 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2015 | 9 | 0.500 |
Why?
| | Myositis | 1 | 2015 | 51 | 0.480 |
Why?
| | Nausea | 1 | 2015 | 110 | 0.480 |
Why?
| | Muscle, Smooth | 1 | 2015 | 157 | 0.460 |
Why?
| | Abdominal Pain | 1 | 2015 | 143 | 0.450 |
Why?
| | Gastrointestinal Microbiome | 4 | 2022 | 640 | 0.400 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 46 | 0.340 |
Why?
| | Spondylarthritis | 2 | 2021 | 45 | 0.310 |
Why?
| | Crohn Disease | 2 | 2021 | 215 | 0.280 |
Why?
| | Intestines | 2 | 2021 | 347 | 0.270 |
Why?
| | Colonoscopy | 2 | 2024 | 236 | 0.270 |
Why?
| | Intestinal Mucosa | 3 | 2019 | 589 | 0.240 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2024 | 86 | 0.210 |
Why?
| | Colonic Polyps | 1 | 2024 | 87 | 0.200 |
Why?
| | Disease Susceptibility | 2 | 2021 | 333 | 0.190 |
Why?
| | Artificial Intelligence | 1 | 2024 | 246 | 0.180 |
Why?
| | Ursodeoxycholic Acid | 1 | 2020 | 19 | 0.180 |
Why?
| | Ustekinumab | 1 | 2020 | 13 | 0.170 |
Why?
| | Dextran Sulfate | 1 | 2020 | 78 | 0.170 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 7 | 0.170 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 60 | 0.160 |
Why?
| | Antiporters | 1 | 2019 | 22 | 0.160 |
Why?
| | Metagenomics | 1 | 2021 | 155 | 0.160 |
Why?
| | Tryptophan | 1 | 2021 | 178 | 0.160 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1839 | 0.160 |
Why?
| | Metabolomics | 2 | 2022 | 652 | 0.150 |
Why?
| | Colitis, Ulcerative | 1 | 2020 | 118 | 0.150 |
Why?
| | Acidosis | 1 | 2019 | 89 | 0.150 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2020 | 1202 | 0.150 |
Why?
| | Aldehydes | 1 | 2019 | 142 | 0.150 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 14 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 758 | 0.150 |
Why?
| | Adenoma | 2 | 2024 | 214 | 0.140 |
Why?
| | Mice, Knockout | 2 | 2020 | 2871 | 0.130 |
Why?
| | Liver Diseases | 1 | 2019 | 290 | 0.130 |
Why?
| | Sexual and Gender Minorities | 1 | 2020 | 194 | 0.130 |
Why?
| | Biopsy | 2 | 2020 | 1092 | 0.130 |
Why?
| | Adenosine | 2 | 2019 | 227 | 0.130 |
Why?
| | Antioxidants | 1 | 2019 | 558 | 0.120 |
Why?
| | CD3 Complex | 1 | 2015 | 103 | 0.120 |
Why?
| | Reproduction | 1 | 2016 | 197 | 0.120 |
Why?
| | Mothers | 1 | 2021 | 730 | 0.110 |
Why?
| | Intestine, Small | 1 | 2015 | 150 | 0.110 |
Why?
| | Microbiota | 1 | 2022 | 728 | 0.110 |
Why?
| | Neutrophils | 1 | 2019 | 1207 | 0.110 |
Why?
| | Inflammation | 3 | 2019 | 2737 | 0.110 |
Why?
| | Lymphocytes | 1 | 2015 | 378 | 0.110 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4057 | 0.100 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2013 | 72 | 0.100 |
Why?
| | Radiography | 1 | 2015 | 796 | 0.100 |
Why?
| | A Kinase Anchor Proteins | 1 | 2013 | 71 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2019 | 1266 | 0.100 |
Why?
| | Humans | 19 | 2024 | 129266 | 0.100 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2013 | 274 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 2016 | 493 | 0.090 |
Why?
| | Colorectal Neoplasms | 2 | 2024 | 752 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1432 | 0.090 |
Why?
| | Cost-Benefit Analysis | 3 | 2020 | 569 | 0.090 |
Why?
| | Liver | 1 | 2019 | 1839 | 0.090 |
Why?
| | Mice | 4 | 2020 | 16915 | 0.080 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 574 | 0.080 |
Why?
| | Infliximab | 2 | 2020 | 100 | 0.080 |
Why?
| | Platelet Membrane Glycoproteins | 1 | 2009 | 35 | 0.080 |
Why?
| | Gram-Positive Bacteria | 1 | 2009 | 44 | 0.080 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 584 | 0.080 |
Why?
| | Early Detection of Cancer | 1 | 2012 | 369 | 0.070 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 207 | 0.070 |
Why?
| | Up-Regulation | 2 | 2019 | 839 | 0.060 |
Why?
| | Animals | 5 | 2020 | 35309 | 0.060 |
Why?
| | Female | 8 | 2024 | 68551 | 0.060 |
Why?
| | HIV Infections | 1 | 2020 | 2719 | 0.060 |
Why?
| | Practice Patterns, Physicians' | 1 | 2012 | 1267 | 0.050 |
Why?
| | Adult | 6 | 2024 | 35495 | 0.050 |
Why?
| | Algorithms | 2 | 2020 | 1613 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2021 | 3377 | 0.050 |
Why?
| | Aged | 2 | 2024 | 22032 | 0.050 |
Why?
| | Middle Aged | 5 | 2024 | 31090 | 0.050 |
Why?
| | Granzymes | 1 | 2021 | 47 | 0.040 |
Why?
| | Prospective Studies | 2 | 2024 | 7123 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 39 | 0.040 |
Why?
| | Azathioprine | 1 | 2020 | 50 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 23 | 0.040 |
Why?
| | Models, Economic | 1 | 2020 | 53 | 0.040 |
Why?
| | Leukocyte Disorders | 1 | 2019 | 10 | 0.040 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2019 | 22 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 106 | 0.040 |
Why?
| | Markov Chains | 1 | 2020 | 117 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 178 | 0.040 |
Why?
| | Receptors, CCR5 | 1 | 2020 | 57 | 0.040 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2019 | 30 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 93 | 0.040 |
Why?
| | Lactation | 1 | 2021 | 169 | 0.040 |
Why?
| | Immune System Diseases | 1 | 2019 | 34 | 0.040 |
Why?
| | Neutrophil Activation | 1 | 2019 | 79 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 169 | 0.040 |
Why?
| | Glutathione Transferase | 1 | 2019 | 102 | 0.040 |
Why?
| | Milk, Human | 1 | 2021 | 151 | 0.040 |
Why?
| | Feces | 1 | 2022 | 441 | 0.040 |
Why?
| | Male | 6 | 2024 | 63512 | 0.040 |
Why?
| | Lysosomes | 1 | 2019 | 137 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 323 | 0.040 |
Why?
| | Ribosomes | 1 | 2019 | 164 | 0.040 |
Why?
| | Antigens, CD | 1 | 2020 | 489 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1040 | 0.030 |
Why?
| | Superoxide Dismutase | 1 | 2019 | 342 | 0.030 |
Why?
| | Biological Products | 1 | 2020 | 200 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1016 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1584 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 595 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1716 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 513 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 757 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1028 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2020 | 481 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 665 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 854 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1688 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1933 | 0.030 |
Why?
| | Proteomics | 1 | 2019 | 1054 | 0.030 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2013 | 361 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 235 | 0.020 |
Why?
| | Hospitalization | 1 | 2022 | 2052 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2019 | 4077 | 0.020 |
Why?
| | Caco-2 Cells | 1 | 2009 | 75 | 0.020 |
Why?
| | Health Care Costs | 1 | 2012 | 367 | 0.020 |
Why?
| | Isoenzymes | 1 | 2009 | 302 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5439 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 316 | 0.020 |
Why?
| | Biological Transport | 1 | 2009 | 404 | 0.020 |
Why?
| | RNA Interference | 1 | 2009 | 450 | 0.020 |
Why?
| | Cell Line | 1 | 2013 | 2779 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2009 | 367 | 0.020 |
Why?
| | Infant | 1 | 2021 | 8975 | 0.020 |
Why?
| | Cell Membrane | 1 | 2009 | 733 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 9745 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4926 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 14461 | 0.010 |
Why?
| | Pregnancy | 1 | 2016 | 6390 | 0.010 |
Why?
| | Young Adult | 1 | 2020 | 12391 | 0.010 |
Why?
| | Hypoxia | 1 | 2009 | 1084 | 0.010 |
Why?
| | Child | 1 | 2022 | 20785 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 20313 | 0.010 |
Why?
|
|
Fennimore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|